Opinion on Therapy Area in South and Central America

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

DDW 2009: Clostridium difficile-associated colitis

A disease that is gaining more importance both in terms of incidence rates and virulence is Clostridium-difficile-associated colitis. Recurrence rates remain high and an emerging strain has proven to be responsible for an increasing number of outbreaks. At Digestive Disease Week 2009, two companies presented promising updates of their respective programs, both with very different approaches.

Published By Datamonitor
15 Jun 2009
Expert View
Expert View

DDW 2009: the anti-TNF battle

Datamonitor attended this year's Digestive Disease Week (DDW) in Chicago, the world's largest gathering of physicians, researchers and opinion leaders in the field of digestive diseases. An ongoing theme of debate at DDW was the timing of biologic therapy introduction in inflammatory bowel diseases, and the efficacy of combination therapy with TNF inhibitors.

Published By Datamonitor
15 Jun 2009
Expert View
Expert View

Depression sufferers still reluctant to see physician

While the number of individuals with major depressive disorder (MDD) is set to grow only minimally in next two decades, the condition still represents a key health risk, for both society and the individual. For example, MDD is a leading cause of disability and under-diagnosis remains a problem. Furthermore, the leading classes of MDD drugs have been linked to increased suicidality.

Published By Datamonitor
07 Jun 2006
CommentWire
CommentWire

Digene: powerful groups favor HPV test

Published By Datamonitor
27 Jul 2001
ResearchWire
ResearchWire

Dyslipidemia: single-pill combinations have their appeal, but not for every market

Published By Datamonitor
23 Apr 2007
Expert View
Expert View

EASD 2009: Lantus defended amid allegations of increased cancer risk

Datamonitor attended this year's European Association for the Study of Diabetes meeting in Vienna, Austria. Following the issuance of guidance on a potential link between Lantus and increased cancer rates in June 2009, presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed.

Published By Datamonitor
14 Oct 2009
Expert View
Expert View

EASL 2010: promising developments in the hepatitis C pipeline

The limitations of the current standard of care for hepatitis C virus infection have left significant room for the development of novel agents, and consequently the pipeline is highly active. Data from studies investigating the use of these agents in hepatitis C-infected patients were a key focus point at this year's European Association of the Study of the Liver meeting.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

ECTRIMS 2010: Biogen Idec demonstrates ongoing commitment to MS through extensive pipeline

As one of the biggest players in multiple sclerosis, Biogen Idec featured strongly at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, using it as a platform to highlight its broad portfolio of products. The most interesting presentation was of data from a Phase II trial of ocrelizumab, showing it to be highly efficacious in relieving MS symptoms.

Published By Datamonitor
02 Nov 2010
Expert View
Expert View

ECTRIMS 2010: despite progress, the advent of personalized medicine remains a distant hope

Datamonitor believes that there is a need for robust and reliable biological markers that can drive diagnosis rates, identify treatment responders, predict disease progression and improve outcomes in MS. However, while lectures during ECTRIMS 2010 highlighted the growing understanding of MS genetics, researchers are still far away from delivering useable clinical tools based on biomarkers.

Published By Datamonitor
02 Nov 2010
Expert View
Expert View

ECTRIMS 2010: exciting times ahead in the MS field

In October, Datamonitor attended the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, during which Biogen Idec, Teva Pharmaceuticals, Sanofi-Aventis and Genzyme presented new data from their late-stage pipeline products. With a wave of novel drugs in the pipeline set to compete with Gilenya and Movectro, the MS space is set to see exciting times ahead.

Published By Datamonitor
02 Nov 2010

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.